forms alliance with Korean CRO
SIRO Clinpharm, a contract research organization (CRO) with presence in
India, Europe, and the US has formed an alliance with DreamCIS, a
leading CRO based in Seoul, South Korea.
DreamCIS offers clinical research services to pharmaceutical companies,
bio venture companies, medical device manufacturers, and functional
“We are one of the leading CROs in South Korea. However,
considering increasing number of global clinical trials and the rapid
growth in Asian clinical trials market, we were looking at associating
with a CRO having a global exposure; not only from business perspective
but also from the perspective of moving up on the learning curve. I
think our mutually beneficial alliance with SIRO is a definite step in
this direction,” said Won-Jung Choi, president, DreamCIS.
“Korea is a rapidly growing clinical trials market due to
pre-approved and well-equipped clinical trial sites, trained
professionals, and transparent and efficient regulatory processes. We
are confident that this alliance will be of immense value addition to
SIRO and widen our global service capabilities,” said Dr
Chetan Tamhankar, CEO, SIRO Clinpharm.
Jubilant expand oncology partnership
Jubilant Biosys and Endo Pharmaceuticals have expanded their drug
discovery partnership in oncology. This one-year-old partnership
focuses on Jubilant delivering preclinical candidates in the
therapeutic area of oncology. Endo owns the late-stage development and
commercialization rights for molecules discovered as part of the
partnership. Jubilant derives research funding and success-based
development and commercialization milestones.
Commenting on this development, Sri Mosur, CEO and president, Global
Drug Discovery and Development, Jubilant Biosys, said, “We
are pleased that we could deliver early success to the discovery
portfolio efforts at Endo Pharmaceuticals and this expansion is a
testimony to Jubilant's focus on building world-class
oncology capabilities, among other therapeutic areas. This
collaboration further reinforces the concept of globally leveraged
R&D that creates a platform for scientists from Endo and
Jubilant to collaborate in finding affordable remedies for cancer
licenses LiquentConnect SaaS solution
Omnicare Clinical Research has licensed LiquentConnect, a hosted
software as a service (SaaS) solution used to create, review, amend and
submit regulatory dossiers. Omnicare Clinical Research is a phase I to
IV global contract research organization serving the biopharmaceutical
and medical device industries.
LiquentConnect enables organizations to produce their own eCTD and
non-electronic submissions without investing in IT infrastructure. All
software and hardware upgrades are managed and executed by Liquent, a
regulatory and clinical services provider for the life sciences
industry. LiquentConnect is fully-executable for eCTD, NeeS and CTD
Omnicare Clinical Research selected Liquent and will be utilizing
LiquentConnect as its hosted solution provider due to its depth of
expertise within the regulatory and life sciences industry. The
benefits of implementing a fully-managed SaaS solution outweighed the
time and resource investment required for other solutions.
sales revenue up by 45%
ClinTec International, a full-service CRO, has achieved organic growth
with a 45 percent increase in global sales revenues over the last 12
months. The company has also expanded its client base and signed new
contracts with 11 of the world's top 25 pharmaceutical firms.
ClinTec has played a key role in 2009 in facilitating complex
restructuring programs for global pharma, who are searching for
innovative ways to optimize their R&D efforts.
builds new facility in Bangalore
Bangalore-based CRAMS player, Kemwell has started the construction
works of its new non-sterile liquid facility in Bangalore. The new
facility will be ready for operation in May 2011, and it will double
Kemwell's current capacity to produce 250 million bottles per
year, with provisions to increase the capacity to another 60 million
bottles annually. The facility will
be highly automated and flexible to serve both large and small scale
requirements of Kemwell's current and new customers. It will
also be designed to meet the quality requirements of regulated markets.
deploys SAS software solution
Clinigene, a Biocon group company and a full-service CRO has deployed
SAS Clinical Data Management -PheedIt solution to accelerate
its clinical research.
Manoj Yasodharan, manager - clinical data management and
biostatistics, Clinigene International, said, “SAS PheedIt
provides a complete solution for clinical data management and analysis.
We have successfully reduced the time to setup new trial projects. SAS
partnership gives control over the entire data management, analysis and